Alaunos Therapeutics (NASDAQ:TCRT) Stock Price Up 1.2%

Alaunos Therapeutics, Inc. (NASDAQ:TCRTGet Rating)’s stock price rose 1.2% during trading on Friday . The stock traded as high as $1.77 and last traded at $1.70. Approximately 1,603,696 shares changed hands during trading, a decline of 39% from the average daily volume of 2,613,958 shares. The stock had previously closed at $1.68.

Analysts Set New Price Targets

TCRT has been the topic of several research reports. Wells Fargo & Company raised shares of Alaunos Therapeutics from an “equal weight” rating to an “overweight” rating and set a $3.00 price objective on the stock in a research note on Wednesday, May 4th. Cantor Fitzgerald reiterated an “overweight” rating on shares of Alaunos Therapeutics in a research note on Monday, May 9th.

Alaunos Therapeutics Price Performance

The company has a 50 day moving average of $1.08. The stock has a market cap of $367.12 million, a PE ratio of -5.31 and a beta of 0.51. The company has a debt-to-equity ratio of 0.21, a quick ratio of 3.29 and a current ratio of 3.29.

Alaunos Therapeutics (NASDAQ:TCRTGet Rating) last issued its quarterly earnings data on Monday, May 16th. The company reported ($0.05) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.09) by $0.04. On average, analysts expect that Alaunos Therapeutics, Inc. will post -0.23 earnings per share for the current year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Janney Montgomery Scott LLC bought a new position in Alaunos Therapeutics during the second quarter valued at approximately $101,000. Steward Partners Investment Advisory LLC bought a new position in Alaunos Therapeutics during the second quarter valued at approximately $45,000. Gamble Jones Investment Counsel bought a new position in Alaunos Therapeutics during the second quarter valued at approximately $76,000. Stephens Inc. AR bought a new position in Alaunos Therapeutics during the second quarter valued at approximately $31,000. Finally, CIBC Private Wealth Group LLC bought a new position in Alaunos Therapeutics during the second quarter valued at approximately $51,000. Institutional investors own 52.16% of the company’s stock.

About Alaunos Therapeutics

(Get Rating)

Alaunos Therapeutics, Inc, a clinical-stage oncology-focused cell therapy company, develops adoptive TCR engineered T-cell therapies. It develops TCR Library, which is in Phase I/II clinical trial for ten TCRs reactive to mutated KRAS, TP53, and EGFR from its TCR library for the treatment of non-small cell lung, colorectal, endometrial, pancreatic, ovarian, and bile duct cancers; hunTR, a human neoantigen T-cell receptor platform; and mbIL-15 to treat solid tumors.

Recommended Stories

Want More Great Investing Ideas?

Receive News & Ratings for Alaunos Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alaunos Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.